PPD strengthens its presence in Eastern Europe

Published: 24-Jun-2008
Media

US-based global contract research organisation PPD is to open an office in Istanbul, Turkey, continuing the company's growth of its Phase II-IV clinical development services in Eastern Europe. PPD will provide clinical monitoring services in key therapeutic areas from this location.


US-based global contract research organisation PPD is to open an office in Istanbul, Turkey, continuing the company's growth of its Phase II-IV clinical development services in Eastern Europe. PPD will provide clinical monitoring services in key therapeutic areas from this location.

The new office strengthens PPD's presence in Eastern Europe beyond Russia and Ukraine, countries where the company is expanding through its pending acquisition of InnoPharm. Eastern Europe is an important, high-growth market for clinical trials and a region PPD has targeted for expansion.

"With a population of 74 million people, Turkey is becoming an attractive place to conduct clinical trials," said Fred Eshelman, ceo of PPD. "Eastern Europe offers recruitment opportunities and quality investigators, and our Istanbul office is an important part of our strategic growth in this region."

  • Companies:
  • PPD
See more

You may also like

Media

PPD opens lab in Singapore and confirms InnoPharm acquisition

Read more
PPD, a US-based global contract research organisation, plans to expand its laboratory services into Singapore in response to growing demand in South-east Asia.

Trending Articles

  1. CHEMUK EXPO CHEMUK 2025 will return on 21st & 22nd May at the NEC in Birmingham.
  2. Hospira acquires worldwide rights to biogeneric filgrastim and manufacturing facility in Croatia <p>Hospira acquires worldwide rights to a biogeneric version of filgrastim.</p>
  3. Optimising excipients to improve bioavailability Guy Tiene, Director of Strategic Content, That's Nice LLC/Nice Insight, discusses excipient market trends, the use of excipients to improve the poor aqueous solubility of increasingly complex drug candidates and how drug developers choose excipient suppliers
  4. Orion enters supply agreement with Peptonic Medical The contract manufacturing organisation has made a commercial supply agreement for the manufacture and packaging of VagiVital
  5. DOW increases global capacity for solid pharma grade PEGs <p>In response to growing global demand for its products, Dow Chemical Co plans a 30% increase in production capacity for its solid grade Carbowax Sentry polyethylene glycols (PEG).</p>

Upcoming event

CPhI Middle East

10–12 December 2024 | Conference | Riyadh, Saudi Arabia See all

You may also like

Media

PPD opens lab in Singapore and confirms InnoPharm acquisition

<p>PPD, a US-based global contract research organisation, plans to expand its laboratory services into Singapore in response to growing demand in South-east Asia.</p>
Media

BioPharma Dynamics proudly sponsor GMCC Excellence Awards

BioPharma Dynamics is proud to continue their headline sponsorship of Greater Manchester Chamber of Commerce Excellence Awards, championing success and achievements of businesses within the Greater Manchester region
Media

Chemspec Europe 2024 conference programme unveiled

A detailed look at key speakers, sessions, and networking opportunities at the international exhibition
Media

Curia receives 2024 CDMO leadership award

Curia recognised for its service in the CDMO industry
Media

Biovian and 3P Biopharmaceuticals join forces to create 3PBIOVIAN

Biovian and 3P Biopharmaceuticals, two leading biologics CDMOs, announce their combination to establish a new pan-European leader in their field
Media

Royal Society of Chemistry and TIB co-create next generation Open Access consortium model

The agreement delivers shared goals of equity for institutions, a community approach and universal open access for authors
Media

Thermo Fisher launches industry’s first off-the-shelf solution to streamline and automate cell therapy manufacturing

Gibco CTS Cellmation Software digitally connects instruments from across Thermo Fisher’s cell therapy portfolio to streamline and automate manufacturing
Subscribe now